Présentation de l'entreprise
Haoxi Health Technology Limited, operating under the ticker HAO, functions as a provider of online marketing solutions within the Chinese market, offering services such as short video marketing through media partners and customized planning solutions. The enterprise is situated in the Communication Services sector, specifically categorized within the Advertising Agencies industry, which defines its operational environment and competitive landscape. This entity currently supports a workforce of 26 employees and holds a market capitalization of $64.20M, generating annual revenue of $32.80M in the trailing twelve months. These valuation and revenue metrics indicate that the company operates as a micro-cap entity with a relatively small scale compared to major advertising conglomerates, suggesting a niche market presence. The disparity between its modest employee count and its specific service offerings highlights a business model likely reliant on high-efficiency digital operations rather than extensive physical infrastructure.
Santé financière
The company reported a revenue of $32.80M and a net income of $3.88M over the trailing twelve months, while recording an EBITDA of $-1,705,292. The significant gap between the positive net income and the negative EBITDA reveals a cost structure where depreciation and amortization expenses, or potentially other non-cash adjustments, are substantial enough to offset operating profitability before these charges, or where the calculation of EBITDA in this specific reporting context reflects a specific accounting treatment distinct from the bottom-line profit. Free cash flow stands at $-6,025,760, which indicates that the company is currently burning cash, thereby limiting its immediate financial flexibility to fund capital expenditures or acquisitions without external financing. Regarding profitability margins, the gross margin is 2.8%, the operating margin is -21.2%, and the profit margin is 11.8%, a configuration where the low gross margin combined with a negative operating margin suggests high operational costs relative to sales, yet the positive profit margin implies significant non-operating income or other comprehensive income affecting the final bottom line. The balance sheet shows $8.62M in cash against $2.02M in debt, resulting in a debt-to-equity ratio of 11.63, which suggests a highly leveraged position given the low equity base, despite the absolute amount of debt being lower than the cash reserves. Liquidity is supported by a current ratio of 5.05, indicating that current assets are more than five times current liabilities, which points to strong short-term liquidity despite the cash burn. Return on Equity is 27.1% while Return on Assets is -6.7%, revealing that management is generating high returns on the shareholders' equity portion, likely driven by the low equity base, but the negative return on assets indicates that the company's total asset base is not generating sufficient operating income to cover its asset costs.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is 0.82, while the forward P/E is N/A, implying that the market currently values the company based on historical earnings rather than projected future growth, likely due to the volatility or unpredictability of its earnings trajectory. The price-to-book ratio is 0.18, which indicates that the market is valuing the company at a significant discount to its book value, suggesting either distressed assets or a market perception that the company's assets are overvalued on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 1.96 and an EV/EBITDA of 2.03 provide additional context, where the low EV/EBITDA suggests the company is cheap relative to its earnings before interest, taxes, depreciation, and amortization, despite the negative EBITDA figure. The stock has traded between a 52-week high of $2.31 and a 52-week low of $0.82, meaning the current price sits within a range where the company has experienced significant volatility over the past year. The beta value of -0.19 indicates that the stock price moves inversely to the broader market or with a volatility profile that does not correlate positively with market movements, offering a unique risk profile for portfolios seeking diversification.
Growth & Income
Revenue growth year-over-year is -64.6%, whereas earnings growth year-over-year is 172.7%, demonstrating that earnings are growing at a much faster rate than revenue, which typically implies a substantial improvement in cost efficiency or a one-time gain boosting profitability despite shrinking sales. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm reinvests all earnings back into the business or retains them rather than distributing them to shareholders. This strategy suggests management prioritizes internal funding for operations or growth initiatives over providing income to investors, a common approach for companies in the early stages of recovery or those with significant cash burn. The overall growth and income profile is characterized by a contraction in sales volume paired with a dramatic expansion in reported earnings, alongside a complete absence of dividend distributions.